Fate Therapeutics, Inc.
- Market cap
- $280.91M
- 52w range
- $0.95 - $3.23
- Beta
- 2.52
- Sector
- Healthcare
- Data quality
- 83/100
- fair value estimate
- $1.55
- Margin of safety
- -32.6%
- Moat score
- 9/100
- Return on equity
- -55.5%
- Debt / equity
- 0.43
- Revenue growth
- -20.3%
- Analyst target
- $5.41
- Target upside
- +135.3%
- Analysts
- 9
About Fate Therapeutics, Inc.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
Valuation
Derived from filed metrics · High confidence (83% of the inputs available)
Moat, fair value and rating computed by our valuation engine (ported from the original Python model).